Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-06-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于调整2024年限制性股票激励计划授予价格的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the adjustment of the grant price of a 2024 restricted stock incentive plan. It details board and supervisory meetings, approvals, and the rationale for adjusting the stock grant price due to dividend distribution and other corporate actions. The document is a formal announcement of a change related to stock incentives, not a full report or financial statement. It does not contain financial results, audit opinions, or detailed financial data. It is not a report publication announcement since it contains substantive content about the adjustment decision. The content fits best under Capital/Financing Update (CAP) because it relates to changes in the company's capital structure and stock incentive plan terms.
2025-06-24 Chinese
董事会薪酬与考核委员会关于2024年限制性股票激励计划第一个归属期归属名单的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the verification of the first vesting period list for a 2024 restricted stock incentive plan. It references compliance with company law, securities law, stock incentive management measures, and listing rules. The content focuses on the approval and legality of the stock incentive vesting for certain individuals. This type of document is related to executive compensation and stock incentive plans, which falls under Remuneration Information filings. The document is short and specific to remuneration and stock incentives, not a full report or announcement of voting results or capital changes. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2025-06-24 Chinese
关于公司2024年限制性股票激励计划第一个归属期归属条件成就的公告
Remuneration Information Classification · 95% confidence The document is a detailed announcement regarding the achievement of vesting conditions for the first vesting period of a 2024 restricted stock incentive plan by the company 科兴生物制药股份有限公司. It includes specifics about the stock incentive plan, approval and implementation details, performance conditions, number of shares vested, and legal and supervisory opinions. The document is not a full annual or interim financial report, nor is it a general regulatory filing or a simple announcement of a report. It is a formal announcement related to the vesting and allocation of restricted stock under a stock incentive plan, which falls under remuneration or compensation disclosures for executives and employees. Therefore, the document best fits the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans and their vesting status.
2025-06-24 Chinese
关于2024年年度权益分派实施后调整回购价格上限的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from a company regarding the adjustment of the upper limit of the share repurchase price following the implementation of the 2024 annual dividend distribution. It details the board resolutions, the reasons for the price adjustment, and the expected number of shares to be repurchased. The content focuses on share repurchase activities and price adjustments rather than financial results, earnings, or annual reports. The document length is relatively short (2230 characters) and it is not a report itself but an announcement about share repurchase price adjustments. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers announcements of share buybacks or sales by the company.
2025-06-20 Chinese
关于转让全资子公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of 100% equity of a wholly-owned subsidiary by the company. It details the transaction parties, pricing, payment terms, and the strategic rationale behind the sale. There are no financial statements or comprehensive financial data presented, nor is this a full report like an annual or interim report. The document is a formal disclosure of a capital transaction involving a subsidiary's equity transfer. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as equity transfers. The document length is 4250 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the correct classification is CAP with high confidence.
2025-06-10 Chinese
第二届监事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed at the 21st meeting of the second Supervisory Board of Kexing Biopharmaceutical Co., Ltd. It details the approval of a proposal to transfer 100% equity of a wholly-owned subsidiary. The document includes meeting attendance, voting results, and a statement of compliance with laws and company articles. It is a formal announcement of a board/management decision rather than a full report or financial statement. There is no indication of it being an annual report, audit report, earnings release, or other financial report. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management bodies.
2025-06-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.